Vyome (HIND) Competitors

$2.07 -0.02 (-0.96%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 +0.06 (+2.66%)

As of 05:41 PM Eastern

HIND vs. DRIO, NSPR, COCH, LUNG, and ECOR

Should you be buying Vyome stock or one of its competitors? The main competitors of Vyome include DarioHealth (DRIO), InspireMD (NSPR), Envoy Medical (COCH), Pulmonx (LUNG), and electroCore (ECOR). These companies are all part of the "medical equipment" industry.

How does Vyome compare to DarioHealth?

DarioHealth (NASDAQ:DRIO) and Vyome (NASDAQ:HIND) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

: Vyome has lower revenue, but higher earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DarioHealth $22.36M 2.61 -$41.71M -$10.43 N/A
Vyome $320K 45.41 -$10.26M -$125.20 N/A
: DarioHealth has a net margin of -186.57% compared to Vyome's net margin of -270.58%. DarioHealth's return on equity of -59.48% beat Vyome's return on equity.
Company Net Margins Return on Equity Return on Assets
DarioHealth -186.57% -59.48% -36.94%
Vyome -270.58% -279.99% -142.04%
: DarioHealth currently has a consensus price target of $35.00, indicating a potential upside of 337.50%. Vyome has a consensus price target of $15.00, indicating a potential upside of 624.64%. Given Vyome's stronger consensus rating and higher possible upside, analysts plainly believe Vyome is more favorable than DarioHealth.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DarioHealth
1 Sell rating(s)
1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
Vyome
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: 33.4% of DarioHealth shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 3.5% of DarioHealth shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: DarioHealth has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Vyome has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
: In the previous week, DarioHealth had 2 more articles in the media than Vyome. MarketBeat recorded 2 mentions for DarioHealth and 0 mentions for Vyome. DarioHealth's average media sentiment score of 0.00 equaled Vyome'saverage media sentiment score.
Company Overall Sentiment
DarioHealth Neutral
Vyome Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DarioHealth	$22.36M	2.61	-$41.71M	-$10.43	N/A
Vyome	$320K	45.41	-$10.26M	-$125.20	N/A

Company	Net Margins	Return on Equity	Return on Assets
DarioHealth	-186.57%	-59.48%	-36.94%
Vyome	-270.58%	-279.99%	-142.04%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DarioHealth	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Vyome	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Overall Sentiment
DarioHealth	Neutral
Vyome	Neutral

Summary

Vyome beats DarioHealth on 8 of the 15 factors compared between the two stocks.

How does Vyome compare to InspireMD?

InspireMD (NYSE:NSPR) and Vyome (NASDAQ:HIND) are both small-cap medical equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

: Vyome has lower revenue, but higher earnings than InspireMD. InspireMD is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InspireMD $8.98M 5.74 -$19.92M -$0.79 N/A
Vyome $320K 45.41 -$10.26M -$125.20 N/A
: Vyome has a net margin of -270.58% compared to InspireMD's net margin of -413.96%. InspireMD's return on equity of -69.42% beat Vyome's return on equity.
Company Net Margins Return on Equity Return on Assets
InspireMD -413.96% -69.42% -57.68%
Vyome -270.58% -279.99% -142.04%
: InspireMD currently has a consensus price target of $4.50, indicating a potential upside of 309.09%. Vyome has a consensus price target of $15.00, indicating a potential upside of 624.64%. Given Vyome's higher possible upside, analysts plainly believe Vyome is more favorable than InspireMD.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD
0 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
3.00
Vyome
1 Sell rating(s)

0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
: 44.8% of InspireMD shares are owned by institutional investors. Comparatively, 22.1% of Vyome shares are owned by institutional investors. 34.1% of InspireMD shares are owned by insiders. Comparatively, 33.0% of Vyome shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: InspireMD has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Vyome has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.
: In the previous week, InspireMD had 11 more articles in the media than Vyome. MarketBeat recorded 11 mentions for InspireMD and 0 mentions for Vyome. InspireMD's average media sentiment score of 0.28 beat Vyome's score of 0.00 indicating that InspireMD is being referred to more favorably in the media.
Company Overall Sentiment
InspireMD Neutral
Vyome Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$8.98M	5.74	-$19.92M	-$0.79	N/A
Vyome	$320K	45.41	-$10.26M	-$125.20	N/A

Company	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Vyome	-270.58%	-279.99%	-142.04%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vyome	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Overall Sentiment
InspireMD	Neutral
Vyome	Neutral

Summary

InspireMD beats Vyome on 9 of the 15 factors compared between the two stocks.

How does Vyome compare to Envoy Medical?

Vyome (NASDAQ:HIND) and Envoy Medical (NASDAQ:COCH) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

: Vyome has a net margin of -270.58% compared to Envoy Medical's net margin of -9,857.26%. Envoy Medical's return on equity of 0.00% beat Vyome's return on equity.
Company Net Margins Return on Equity Return on Assets
Vyome -270.58% -279.99% -142.04%
Envoy Medical -9,857.26% N/A -256.65%
: Vyome currently has a consensus price target of $15.00, suggesting a potential upside of 624.64%. Envoy Medical has a consensus price target of $6.00, suggesting a potential upside of 760.83%. Given Envoy Medical's higher possible upside, analysts plainly believe Envoy Medical is more favorable than Vyome.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vyome
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Envoy Medical
1 Sell rating(s)

1 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.25
: In the previous week, Envoy Medical had 1 more articles in the media than Vyome. MarketBeat recorded 1 mentions for Envoy Medical and 0 mentions for Vyome. Vyome's average media sentiment score of 0.00 equaled Envoy Medical'saverage media sentiment score.
Company Overall Sentiment
Vyome Neutral
Envoy Medical Neutral
: Vyome has higher revenue and earnings than Envoy Medical. Envoy Medical is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vyome $320K 45.41 -$10.26M -$125.20 N/A
Envoy Medical $241K 222.35 -$23.76M -$1.22 N/A
: 22.1% of Vyome shares are held by institutional investors. Comparatively, 8.6% of Envoy Medical shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 7.1% of Envoy Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Vyome has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-279.99%	-142.04%
Envoy Medical	-9,857.26%	N/A	-256.65%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Envoy Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Company	Overall Sentiment
Vyome	Neutral
Envoy Medical	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	45.41	-$10.26M	-$125.20	N/A
Envoy Medical	$241K	222.35	-$23.76M	-$1.22	N/A

Summary

Vyome beats Envoy Medical on 9 of the 15 factors compared between the two stocks.

How does Vyome compare to Pulmonx?

Vyome (NASDAQ:HIND) and Pulmonx (NASDAQ:LUNG) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

: Pulmonx has a net margin of -60.09% compared to Vyome's net margin of -270.58%. Pulmonx's return on equity of -87.11% beat Vyome's return on equity.
Company Net Margins Return on Equity Return on Assets
Vyome -270.58% -279.99% -142.04%
Pulmonx -60.09% -87.11% -38.49%
: Vyome currently has a consensus price target of $15.00, suggesting a potential upside of 624.64%. Pulmonx has a consensus price target of $5.38, suggesting a potential upside of 323.51%. Given Vyome's stronger consensus rating and higher possible upside, equities analysts plainly believe Vyome is more favorable than Pulmonx.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vyome
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
Pulmonx
1 Sell rating(s)

3 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
2.38
: In the previous week, Pulmonx had 15 more articles in the media than Vyome. MarketBeat recorded 15 mentions for Pulmonx and 0 mentions for Vyome. Pulmonx's average media sentiment score of 0.22 beat Vyome's score of 0.00 indicating that Pulmonx is being referred to more favorably in the news media.
Company Overall Sentiment
Vyome Neutral
Pulmonx Neutral
: Vyome has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vyome $320K 45.41 -$10.26M -$125.20 N/A
Pulmonx $88.55M 0.61 -$54M -$1.30 N/A
: 22.1% of Vyome shares are held by institutional investors. Comparatively, 91.0% of Pulmonx shares are held by institutional investors. 33.0% of Vyome shares are held by insiders. Comparatively, 6.8% of Pulmonx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
: Vyome has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-279.99%	-142.04%
Pulmonx	-60.09%	-87.11%	-38.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pulmonx	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Company	Overall Sentiment
Vyome	Neutral
Pulmonx	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	45.41	-$10.26M	-$125.20	N/A
Pulmonx	$88.55M	0.61	-$54M	-$1.30	N/A

Summary

Pulmonx beats Vyome on 9 of the 16 factors compared between the two stocks.

How does Vyome compare to electroCore?

Vyome (NASDAQ:HIND) and electroCore (NASDAQ:ECOR) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

: 22.1% of Vyome shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 33.0% of Vyome shares are held by company insiders. Comparatively, 13.8% of electroCore shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
: electroCore has a net margin of -43.60% compared to Vyome's net margin of -270.58%. Vyome's return on equity of -279.99% beat electroCore's return on equity.
Company Net Margins Return on Equity Return on Assets
Vyome -270.58% -279.99% -142.04%
electroCore -43.60% -1,956.38% -74.62%
: Vyome presently has a consensus price target of $15.00, suggesting a potential upside of 624.64%. electroCore has a consensus price target of $18.00, suggesting a potential upside of 157.14%. Given Vyome's stronger consensus rating and higher probable upside, research analysts plainly believe Vyome is more favorable than electroCore.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vyome
1 Sell rating(s)
0 Hold rating(s)

3 Buy rating(s)

0 Strong Buy rating(s)
2.50
electroCore
1 Sell rating(s)

1 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, electroCore had 3 more articles in the media than Vyome. MarketBeat recorded 3 mentions for electroCore and 0 mentions for Vyome. electroCore's average media sentiment score of 0.46 beat Vyome's score of 0.00 indicating that electroCore is being referred to more favorably in the news media.
Company Overall Sentiment
Vyome Neutral
electroCore Neutral
: Vyome has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500. Comparatively, electroCore has a beta of 0.68, indicating that its share price is 32% less volatile than the S&P 500.
: Vyome has higher earnings, but lower revenue than electroCore. electroCore is trading at a lower price-to-earnings ratio than Vyome, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vyome $320K 45.41 -$10.26M -$125.20 N/A
electroCore $32.03M 1.77 -$13.97M -$1.65 N/A

Company	Net Margins	Return on Equity	Return on Assets
Vyome	-270.58%	-279.99%	-142.04%
electroCore	-43.60%	-1,956.38%	-74.62%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vyome	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
Vyome	Neutral
electroCore	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vyome	$320K	45.41	-$10.26M	-$125.20	N/A
electroCore	$32.03M	1.77	-$13.97M	-$1.65	N/A

Summary

Vyome beats electroCore on 9 of the 16 factors compared between the two stocks.

Get Vyome News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIND vs. The Competition

Export

Metric	Vyome	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$14.53M	$3.86B	$4.21B	$11.87B
Dividend Yield	N/A	N/A	5.61%	5.21%
P/E Ratio	-0.02	4.05	23.40	28.47
Price / Sales	45.41	323.04	186.69	60.92
Price / Cash	N/A	3.96	52.82	36.52
Price / Book	3.09	3.81	38.31	6.67
Net Income	-$10.26M	-$76.79M	$114.66M	$332.53M
7 Day Performance	-1.43%	-0.64%	1.23%	2.01%
1 Month Performance	-2.82%	-2.29%	5.54%	9.19%
1 Year Performance	N/A	52.89%	18.68%	39.59%

Vyome Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIND Vyome	2.0407 of 5 stars	$2.07 -1.0%	$15.00 +624.6%	N/A	$14.53M	$320K	N/A	50	Analyst Forecast
DRIO DarioHealth	1.8947 of 5 stars	$7.50 +1.4%	$35.00 +366.7%	N/A	$54.75M	$22.36M	N/A	200	News Coverage Gap Up
NSPR InspireMD	3.1521 of 5 stars	$1.14 flat	$5.00 +338.6%	N/A	$53.46M	$8.98M	N/A	50	News Coverage Analyst Forecast Gap Down High Trading Volume
COCH Envoy Medical	2.214 of 5 stars	$0.68 +6.7%	$6.00 +786.5%	N/A	$52.03M	$241K	N/A	34	Upcoming Earnings
LUNG Pulmonx	2.4743 of 5 stars	$1.20 -2.4%	$5.38 +348.2%	N/A	$50.68M	$90.50M	N/A	250	Earnings Report Analyst Downgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HIND) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vyome (HIND) Competitors